Pulmonx Corp., a medical device company that provides the Zephyr
valve system for severe emphysema, disclosed plans for an initial public
offering.
Pulmonx previously filed confidentially for an IPO. The Redwood City,
Calif., company is seeking a Nasdaq Global Market listing under the
symbol LUNG.
Boston Scientific Corp. owns 30% of Pulmonx. Last May, Pulmonx closed $65 million of equity financing led by Ally Bridge Group.
Pulmonx had 2019 revenue of $32.6 million, compared with $20 million in 2018.
https://www.marketscreener.com/BOSTON-SCIENTIFIC-CORPORA-11935/news/Boston-Scientific-Medical-Device-Company-Pulmonx-Files-for-IPO-30085387/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.